Tocagen exists for you, the patient. You drive us to pursue the discovery, development and commercialization of novel products that treat cancer, with an initial focus on advanced diseases for which there are no adequate therapies today.
We believe that our cancer-selective gene therapy platform provides an important opportunity for treating cancers because it is designed to safely and selectively provide long-term presence of a therapeutic gene which activates your immune system against the cancer, potentially helping control or overcome your cancer. View our scientific publications.
Ongoing clinical trials of our lead product candidate Toca 511 & Toca FC have shown potential benefits, including extended overall survival compared to historical benchmarks and a favorable safety profile. Our Phase 2/3 study, Toca 5, is designed to provide evidence that our novel approach extends life for patients with recurrent high grade glioma (HGG) and takes us a step closer towards our vision. Learn more about the Toca 5 study. But this is just the beginning. We plan to develop additional drugs which are designed to activate the patient’s immune system against their cancer from within.
Also, we see potential opportunity to extend Toca 511 & Toca FC to other forms of cancer such as colorectal cancer, renal cell carcinoma, metastatic melanoma, and brain metastases from breast and lung cancers.
Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study. Find more info with the Tocagen Blog